vs
Side-by-side financial comparison of Allegion (ALLE) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Allegion is the larger business by last-quarter revenue ($1.0B vs $699.9M, roughly 1.5× QuidelOrtho Corp). Allegion runs the higher net margin — 13.4% vs -104.7%, a 118.1% gap on every dollar of revenue. On growth, Allegion posted the faster year-over-year revenue change (9.7% vs -3.7%). Over the past eight quarters, Allegion's revenue compounded faster (3.5% CAGR vs -2.9%).
Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers, controls, and exit devices; locks, locksets, portable locks, and key systems and services; electronic security products and access control systems; time, attendance, and workforce productivity systems; doors and door systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facili...
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
ALLE vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $699.9M |
| Net Profit | $138.1M | $-733.0M |
| Gross Margin | 44.0% | — |
| Operating Margin | 18.9% | -100.7% |
| Net Margin | 13.4% | -104.7% |
| Revenue YoY | 9.7% | -3.7% |
| Net Profit YoY | -6.8% | -3583.4% |
| EPS (diluted) | — | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | $699.9M | ||
| Q2 25 | $1.0B | $613.9M | ||
| Q1 25 | $941.9M | $692.8M | ||
| Q4 24 | $945.6M | $707.8M | ||
| Q3 24 | $967.1M | $727.1M | ||
| Q2 24 | $965.6M | $637.0M |
| Q1 26 | $138.1M | — | ||
| Q4 25 | $147.5M | — | ||
| Q3 25 | $188.4M | $-733.0M | ||
| Q2 25 | $159.7M | $-255.4M | ||
| Q1 25 | $148.2M | $-12.7M | ||
| Q4 24 | $144.1M | $-178.4M | ||
| Q3 24 | $174.2M | $-19.9M | ||
| Q2 24 | $155.4M | $-147.7M |
| Q1 26 | 44.0% | — | ||
| Q4 25 | 44.5% | — | ||
| Q3 25 | 45.8% | — | ||
| Q2 25 | 45.6% | — | ||
| Q1 25 | 44.9% | — | ||
| Q4 24 | 44.1% | — | ||
| Q3 24 | 44.7% | — | ||
| Q2 24 | 44.4% | — |
| Q1 26 | 18.9% | — | ||
| Q4 25 | 20.3% | — | ||
| Q3 25 | 21.8% | -100.7% | ||
| Q2 25 | 21.5% | -29.4% | ||
| Q1 25 | 20.9% | 4.7% | ||
| Q4 24 | 19.5% | -14.2% | ||
| Q3 24 | 22.2% | 2.1% | ||
| Q2 24 | 21.6% | -18.4% |
| Q1 26 | 13.4% | — | ||
| Q4 25 | 14.3% | — | ||
| Q3 25 | 17.6% | -104.7% | ||
| Q2 25 | 15.6% | -41.6% | ||
| Q1 25 | 15.7% | -1.8% | ||
| Q4 24 | 15.2% | -25.2% | ||
| Q3 24 | 18.0% | -2.7% | ||
| Q2 24 | 16.1% | -23.2% |
| Q1 26 | — | — | ||
| Q4 25 | $1.70 | — | ||
| Q3 25 | $2.18 | $-10.78 | ||
| Q2 25 | $1.85 | $-3.77 | ||
| Q1 25 | $1.71 | $-0.19 | ||
| Q4 24 | $1.65 | $-2.54 | ||
| Q3 24 | $1.99 | $-0.30 | ||
| Q2 24 | $1.77 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $308.9M | $98.1M |
| Total DebtLower is stronger | $2.0B | $2.5B |
| Stockholders' EquityBook value | $2.1B | $2.0B |
| Total Assets | $5.3B | $5.7B |
| Debt / EquityLower = less leverage | 0.97× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $308.9M | — | ||
| Q4 25 | $356.2M | — | ||
| Q3 25 | $302.7M | $98.1M | ||
| Q2 25 | $656.8M | $151.7M | ||
| Q1 25 | $494.5M | $127.1M | ||
| Q4 24 | $503.8M | $98.3M | ||
| Q3 24 | $878.9M | $143.7M | ||
| Q2 24 | $747.5M | $107.0M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.1B | $2.5B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.0B | $2.1B | ||
| Q4 24 | $2.0B | $2.1B | ||
| Q3 24 | $2.4B | $2.2B | ||
| Q2 24 | $2.4B | $2.2B |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.9B | $2.0B | ||
| Q2 25 | $1.8B | $2.8B | ||
| Q1 25 | $1.6B | $3.0B | ||
| Q4 24 | $1.5B | $3.0B | ||
| Q3 24 | $1.6B | $3.2B | ||
| Q2 24 | $1.4B | $3.2B |
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.2B | $5.7B | ||
| Q2 25 | $4.9B | $6.4B | ||
| Q1 25 | $4.6B | $6.5B | ||
| Q4 24 | $4.5B | $6.4B | ||
| Q3 24 | $5.0B | $6.8B | ||
| Q2 24 | $4.8B | $6.7B |
| Q1 26 | 0.97× | — | ||
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.07× | 1.23× | ||
| Q2 25 | 1.16× | 0.74× | ||
| Q1 25 | 1.24× | 0.70× | ||
| Q4 24 | 1.33× | 0.72× | ||
| Q3 24 | 1.53× | 0.68× | ||
| Q2 24 | 1.69× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $101.3M | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | 2.0% | 7.0% |
| Cash ConversionOCF / Net Profit | 0.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $101.3M | — | ||
| Q4 25 | $240.1M | — | ||
| Q3 25 | $229.5M | $-45.5M | ||
| Q2 25 | $209.7M | $-46.8M | ||
| Q1 25 | $104.5M | $65.6M | ||
| Q4 24 | $219.0M | $63.7M | ||
| Q3 24 | $231.9M | $117.9M | ||
| Q2 24 | $173.0M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $200.5M | — | ||
| Q3 25 | $209.8M | $-94.7M | ||
| Q2 25 | $192.0M | $-84.3M | ||
| Q1 25 | $83.4M | $9.4M | ||
| Q4 24 | $194.9M | $16.5M | ||
| Q3 24 | $212.0M | $71.4M | ||
| Q2 24 | $152.1M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | — | ||
| Q3 25 | 19.6% | -13.5% | ||
| Q2 25 | 18.8% | -13.7% | ||
| Q1 25 | 8.9% | 1.4% | ||
| Q4 24 | 20.6% | 2.3% | ||
| Q3 24 | 21.9% | 9.8% | ||
| Q2 24 | 15.8% | -20.9% |
| Q1 26 | 2.0% | — | ||
| Q4 25 | 3.8% | — | ||
| Q3 25 | 1.8% | 7.0% | ||
| Q2 25 | 1.7% | 6.1% | ||
| Q1 25 | 2.2% | 8.1% | ||
| Q4 24 | 2.5% | 6.7% | ||
| Q3 24 | 2.1% | 6.4% | ||
| Q2 24 | 2.2% | 5.5% |
| Q1 26 | 0.73× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 1.52× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALLE
| Allegion Americas | $809.9M | 78% |
| Allegion International | $223.7M | 22% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
